Risk factors and outcomes of imipenem-resistant Acinetobacter bloodstream infection in North-Eastern Malaysia

Asian Pac J Trop Biomed. 2011 Aug;1(4):313-5. doi: 10.1016/S2221-1691(11)60050-6.

Abstract

Objective: To determine the risk factors and outcomes of imipenem-resistant Acinetobacter baumannii (IRAB) bloodstream infection (BSI) cases, since there is very little publication on Acinetobacter baumannii infections from Malaysia.

Methods: A cross sectional study of 41 cases (73.2%) of imipenem-sensitive Acinetobacter baumanii (ISAB) and 15 cases (26.8%) of IRAB was conducted in a teaching hospital which was located at North-Eastern state of Malaysia.

Results: There was no independent risk factor for IRAB BSI identified but IRAB BSI was significantly associated with longer bacteraemic days [OR 1.23 (95% CI 1.01, 1.50)]. Although prior use of carbepenems and cephalosporin were higher among IRAB than ISAB group, statistically they were not significant. There was no significant difference in term of outcomes between the two groups.

Conclusions: Although statistically not significant, this analysis compliments previous publication highlighting the importance of appropriate empiric antibiotic usage in hospital especially carbepenems and need further evaluation with bigger subjects.

Keywords: Acinetobacter baumannii; Bacteraemia; Multi-drug resistant; Outcomes; Risk factors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acinetobacter Infections / drug therapy*
  • Acinetobacter Infections / epidemiology
  • Acinetobacter Infections / microbiology
  • Acinetobacter baumannii / drug effects*
  • Acinetobacter baumannii / isolation & purification
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use*
  • Bacteremia / drug therapy*
  • Bacteremia / epidemiology
  • Bacteremia / microbiology
  • Case-Control Studies
  • Cross-Sectional Studies
  • Female
  • Hospitals, Teaching
  • Humans
  • Imipenem / pharmacology
  • Imipenem / therapeutic use*
  • Malaysia / epidemiology
  • Male
  • Middle Aged
  • Risk Factors
  • Treatment Outcome
  • Young Adult
  • beta-Lactam Resistance*

Substances

  • Anti-Bacterial Agents
  • Imipenem